Cargando…
Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest
Manual ELISA assays are the most commonly used methods for quantification of biomarkers; however, they often show inter- and intra-laboratory variability that limits their wide use. Here, we compared the Innotest ELISA method with two fully automated platforms (Lumipulse and Elecsys) to determine wh...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970049/ https://www.ncbi.nlm.nih.gov/pubmed/33746733 http://dx.doi.org/10.3389/fnagi.2021.604119 |
_version_ | 1783666358258499584 |
---|---|
author | Dakterzada, Farida López-Ortega, Ricard Arias, Alfonso Riba-Llena, Iolanda Ruiz-Julián, Maria Huerto, Raquel Tahan, Nuria Piñol-Ripoll, Gerard |
author_facet | Dakterzada, Farida López-Ortega, Ricard Arias, Alfonso Riba-Llena, Iolanda Ruiz-Julián, Maria Huerto, Raquel Tahan, Nuria Piñol-Ripoll, Gerard |
author_sort | Dakterzada, Farida |
collection | PubMed |
description | Manual ELISA assays are the most commonly used methods for quantification of biomarkers; however, they often show inter- and intra-laboratory variability that limits their wide use. Here, we compared the Innotest ELISA method with two fully automated platforms (Lumipulse and Elecsys) to determine whether these new methods can provide effective substitutes for ELISA assays. We included 149 patients with AD (n = 34), MCI (n = 94) and non-AD dementias (n = 21). Aβ42, T-tau, and P-tau were quantified using the ELISA method (Innotest, Fujirebio Europe), CLEIA method on a Lumipulse G600II (Fujirebio Diagnostics), and ECLIA method on a Cobas e 601 (Roche Diagnostics) instrument. We found a high correlation between the three methods, although there were systematic differences between biomarker values measured by each method. Both Lumipulse and Elecsys methods were highly concordant with clinical diagnoses, and the combination of Lumipulse Aβ42 and P-tau had the highest discriminating power (AUC 0.915, 95% CI 0.822–1.000). We also assessed the agreement of AT(N) classification for each method with AD diagnosis. Although differences were not significant, the use of Aβ42/Aβ40 ratio instead of Aβ42 alone in AT(N) classification enhanced the diagnostic accuracy (AUC 0.798, 95% CI 0.649–0.947 vs. AUC 0.778, 95% CI 0.617–0.939). We determined the cut-offs for the Lumipulse and Elecsys assays based on the Aβ42/Aβ40 ratio ± status as a marker of amyloid pathology, and these cut-offs were consistent with those recommended by manufacturers, which had been determined based on visual amyloid PET imaging or diagnostic accuracy. Finally, the biomarker ratios (P-tau/Aβ42 and T-tau/Aβ42) were more consistent with the Aβ42/Aβ40 ratio for both Lumipulse and Elecsys methods, and Elecsys P-tau/Aβ42 had the highest consistency with amyloid pathology (AUC 0.994, 95% CI 0.986–1.000 and OPA 96.4%) at the ≥0.024 cut-off. The Lumipulse and Elecsys cerebrospinal fluid (CSF) AD assays showed high analytical and clinical performances. As both automated platforms were standardized for reference samples, their use is recommended for the measurement of CSF AD biomarkers compared with unstandardized manual methods, such as Innotest ELISA, that have demonstrated a high inter and intra-laboratory variability. |
format | Online Article Text |
id | pubmed-7970049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79700492021-03-19 Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest Dakterzada, Farida López-Ortega, Ricard Arias, Alfonso Riba-Llena, Iolanda Ruiz-Julián, Maria Huerto, Raquel Tahan, Nuria Piñol-Ripoll, Gerard Front Aging Neurosci Neuroscience Manual ELISA assays are the most commonly used methods for quantification of biomarkers; however, they often show inter- and intra-laboratory variability that limits their wide use. Here, we compared the Innotest ELISA method with two fully automated platforms (Lumipulse and Elecsys) to determine whether these new methods can provide effective substitutes for ELISA assays. We included 149 patients with AD (n = 34), MCI (n = 94) and non-AD dementias (n = 21). Aβ42, T-tau, and P-tau were quantified using the ELISA method (Innotest, Fujirebio Europe), CLEIA method on a Lumipulse G600II (Fujirebio Diagnostics), and ECLIA method on a Cobas e 601 (Roche Diagnostics) instrument. We found a high correlation between the three methods, although there were systematic differences between biomarker values measured by each method. Both Lumipulse and Elecsys methods were highly concordant with clinical diagnoses, and the combination of Lumipulse Aβ42 and P-tau had the highest discriminating power (AUC 0.915, 95% CI 0.822–1.000). We also assessed the agreement of AT(N) classification for each method with AD diagnosis. Although differences were not significant, the use of Aβ42/Aβ40 ratio instead of Aβ42 alone in AT(N) classification enhanced the diagnostic accuracy (AUC 0.798, 95% CI 0.649–0.947 vs. AUC 0.778, 95% CI 0.617–0.939). We determined the cut-offs for the Lumipulse and Elecsys assays based on the Aβ42/Aβ40 ratio ± status as a marker of amyloid pathology, and these cut-offs were consistent with those recommended by manufacturers, which had been determined based on visual amyloid PET imaging or diagnostic accuracy. Finally, the biomarker ratios (P-tau/Aβ42 and T-tau/Aβ42) were more consistent with the Aβ42/Aβ40 ratio for both Lumipulse and Elecsys methods, and Elecsys P-tau/Aβ42 had the highest consistency with amyloid pathology (AUC 0.994, 95% CI 0.986–1.000 and OPA 96.4%) at the ≥0.024 cut-off. The Lumipulse and Elecsys cerebrospinal fluid (CSF) AD assays showed high analytical and clinical performances. As both automated platforms were standardized for reference samples, their use is recommended for the measurement of CSF AD biomarkers compared with unstandardized manual methods, such as Innotest ELISA, that have demonstrated a high inter and intra-laboratory variability. Frontiers Media S.A. 2021-03-04 /pmc/articles/PMC7970049/ /pubmed/33746733 http://dx.doi.org/10.3389/fnagi.2021.604119 Text en Copyright © 2021 Dakterzada, López-Ortega, Arias, Riba-Llena, Ruiz-Julián, Huerto, Tahan and Piñol-Ripoll. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Dakterzada, Farida López-Ortega, Ricard Arias, Alfonso Riba-Llena, Iolanda Ruiz-Julián, Maria Huerto, Raquel Tahan, Nuria Piñol-Ripoll, Gerard Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest |
title | Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest |
title_full | Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest |
title_fullStr | Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest |
title_full_unstemmed | Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest |
title_short | Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest |
title_sort | assessment of the concordance and diagnostic accuracy between elecsys and lumipulse fully automated platforms and innotest |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970049/ https://www.ncbi.nlm.nih.gov/pubmed/33746733 http://dx.doi.org/10.3389/fnagi.2021.604119 |
work_keys_str_mv | AT dakterzadafarida assessmentoftheconcordanceanddiagnosticaccuracybetweenelecsysandlumipulsefullyautomatedplatformsandinnotest AT lopezortegaricard assessmentoftheconcordanceanddiagnosticaccuracybetweenelecsysandlumipulsefullyautomatedplatformsandinnotest AT ariasalfonso assessmentoftheconcordanceanddiagnosticaccuracybetweenelecsysandlumipulsefullyautomatedplatformsandinnotest AT riballenaiolanda assessmentoftheconcordanceanddiagnosticaccuracybetweenelecsysandlumipulsefullyautomatedplatformsandinnotest AT ruizjulianmaria assessmentoftheconcordanceanddiagnosticaccuracybetweenelecsysandlumipulsefullyautomatedplatformsandinnotest AT huertoraquel assessmentoftheconcordanceanddiagnosticaccuracybetweenelecsysandlumipulsefullyautomatedplatformsandinnotest AT tahannuria assessmentoftheconcordanceanddiagnosticaccuracybetweenelecsysandlumipulsefullyautomatedplatformsandinnotest AT pinolripollgerard assessmentoftheconcordanceanddiagnosticaccuracybetweenelecsysandlumipulsefullyautomatedplatformsandinnotest |